

## Surveillance report

Surveillance generated by nf-ncov-voc for Gamma variant

### Date

This report is generated on 2022-02-14 using 184213 number of genomes collected between 2020-02-25 and 2022-01-09

## Pango Lineages

Pango Lineages in this report ['P.1', 'P.1.10', 'P.1.12', 'P.1.12.1', 'P.1.14', 'P.1.15', 'P.1.17', 'P.1.7']

## Indicator

This table contains key indicators identified

Indicator	Sub-categories from POKAY	Mutations
Transmissibility between humans	transmissibility	p.D138Y, p.D614G, p.E484K, p.H655Y, p.L18F, p.N501Y, p.P26S, p.R190S, p.T20N
Infection Severity	ACE2 receptor binding affinity, viral load, outcome hazard ratio	p.D138Y, p.D614G, p.E484K, p.H655Y, p.K417T, p.L18F, p.L5F, p.N501Y, p.P26S, p.P681H, p.R190S, p.T1027I, p.T20N
Immunity after natural infection	convalescent plasma escape, reinfection, humoral response durability	p.D138Y, p.D614G, p.E484K, p.H655Y, p.K417T, p.L18F, p.N501Y, p.P26S, p.R190S, p.T1027I, p.T20N, p.V1176F
Vaccines	vaccine neutralization efficacy	p.D138Y, p.D614G, p.E484K, p.H655Y, p.K417T, p.L18F, p.N501Y, p.P26S, p.P681H, p.R190S, p.T1027I, p.T20N, p.V1176F
Monoclonal antibodies	monoclonal antibody serial passage escape, pharmaceutical effectiveness	p.E484K, p.K378N, p.K417T, p.N501Y, p.R246G
Diagnostics	clinical indicators, antigenic test failure, symptom prevalence	

## Mutation Significance

This table contains key functional impacts of mutations identified

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.R190S	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan
p.R190S	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan
p.R190S	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11236	G	T	nan
p.R190S	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11236	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.R190S	antibody epitope effects	The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria ( extasciitildewild type), with only 64% neutralization at 10 g/mL. Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed. Given that there is likely a single super-site ("i") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primarily anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with neutralization of Victoria ( extasciitildewild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1, with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11236	G	T	nan
p.R190S	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma binding	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.R190S	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	In 13 plasma collected extasciitidelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11236	G	T	nan
p.R190S	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11236	G	T	nan
p.R190S	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11236	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.R190S	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11236	G	T	nan
p.R190S	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11236	G	T	nan
p.R190S	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11236	G	T	nan
p.R190S	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11236	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.R190S	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11236	G	T	nan
p.R190S	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11236	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.R190S	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11236	G	T	nan
p.R190S	vaccinee plasma binding	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan
p.R190S	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11236	G	T	nan
p.R190S	virion structure	Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type)	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11236	G	T	nan
p.R190S	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11236	G	T	nan
p.P681H	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	P.1.7	Gong et al. (2021)	2	C	A	nan
p.P681H	antibody epitope effects	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	P.1.7	Chen et al. (2021)	2	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P681H	antibody epitope effects	Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B.1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	P.1.7	Haynes et al. (2021)	2	C	A	nan
p.P681H	antibody epitope effects	This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	P.1.7	Johnson et al. (2020)	2	C	A	nan
p.P681H	convalescent plasma binding	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.7	Gong et al. (2021)	2	C	A	nan
p.P681H	trafficking	While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases, this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account for the increased in transmission and disease severity attributed to this variant of concern (VOC).	P.1.7	Lubinski et al. (2021)	2	C	A	nan
p.P681H	trafficking	This mutation in the first base of the furin cleavage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphatase recognition site at S680. In a homologous site in Infectious Bronchitis Virus (IBV, Gamma-coronaviruses), abolition of S680 phosphorylation improves furin cleavage (and presumably cell entry).	P.1.7	Maaroufi (2021)	2	C	A	nan
p.P681H	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one amino acid upstream of the RXXR recognition pattern.	P.1.7	Tada et al. (2021)	2	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P681H	vaccine neutralization efficacy	No significant change in virus neutralization by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	P.1.7	Zuckerman et al. (2021)	2	C	A	nan
p.P681H	vaccinee plasma binding	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.7	Gong et al. (2021)	2	C	A	nan
p.P681H	virion structure	The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation, due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	P.1.7	Tada et al. (2021)	2	C	A	nan
p.H655Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan
p.H655Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan
p.H655Y	anthropozoonotic events	Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11248	C	T	nan
p.H655Y	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11248	C	T	nan
p.H655Y	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11248	C	T	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.H655Y	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma binding	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	In 13 plasma collected extasciitidelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11248	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.H655Y	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11248	C	T	nan
p.H655Y	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11248	C	T	nan
p.H655Y	homoplasy	In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Borges et al. (2021)	11248	C	T	nan
p.H655Y	outcome hazard ratio	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Funk et al. (2021)	11248	C	T	nan
p.H655Y	outcome hazard ratio	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves: The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ribas Freitas et al. (2021)	11248	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.H655Y	outcome hazard ratio	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged 30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably, the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases. Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil. [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Santos de Oliveira et al. (2021)	11248	C	T	nan
p.H655Y	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11248	C	T	nan
p.H655Y	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11248	C	T	nan
p.H655Y	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11248	C	T	nan
p.H655Y	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11248	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.H655Y	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.H655Y	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11248	C	T	nan
p.H655Y	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11248	C	T	nan
p.H655Y	vaccinee plasma binding	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.H655Y	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11248	C	T	nan
p.H655Y	virion structure	Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11248	C	T	nan
p.H655Y	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11248	C	T	nan
p.P26S	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.P26S	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.P26S	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11263	C	T	nan
p.P26S	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P26S	antibody epitope effects	The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (extasciitildewild type), with only 64% neutralization at 10 g/mL. Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed. Given that there is likely a single super-site ("i") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primarily anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with neutralization of Victoria (extasciitildewild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1, with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11263	C	T	nan
p.P26S	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma binding	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P26S	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	In 13 plasma collected extasciitidelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11263	C	T	nan
p.P26S	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.P26S	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P26S	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11263	C	T	nan
p.P26S	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11263	C	T	nan
p.P26S	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.P26S	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P26S	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11263	C	T	nan
p.P26S	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.P26S	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.P26S	vaccinee plasma binding	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.P26S	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.P26S	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.L5F	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	P.1.7	Gong et al. (2021)	2	C	T	nan
p.L5F	convalescent plasma binding	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.7	Gong et al. (2021)	2	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L5F	vaccinee plasma binding	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.7	Gong et al. (2021)	2	C	T	nan
p.E484K	ACE2 receptor binding affinity	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild type RBD by increasing the k(on) and decreasing the k(off) rate constants.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to extasciitilde15 fold higher than WT RBD (KD extasciitilde5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	This combination showed extasciitilde3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Collier et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with extasciitilde19x greater affinity than wild type.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	This variant appears twice in the experiments, with slightly different affinities (both extasciitilde1.2x decrease in binding relative to D614G) using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	ACE2 receptor binding affinity	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Laffebber et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Studying the key covariants in lineage of concern 501Y.V2, observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Liu et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Using Microscale Thermophoresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ramanathan et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Experimentally, ACE2 binding affinity increased 0.06 fold	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Starr et al. (2020)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tian et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tian et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Vogel et al. (2021)	11262	G	A	nan
p.E484K	ACE2 receptor binding affinity	Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Zahradnik et al. (2021)	11262	G	A	nan
p.E484K	T cell evasion	Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared to have no substantial or differential impact on T cell responses.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Reynolds et al. (2021)	11262	G	A	nan
p.E484K	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Collier et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding, but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response) show pronounced increase in binding to the variant.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gaebler et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Li et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistance to 4 antibodies, and broad low level resistance against much of the rest of the panel.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Liu et al. (2020)	11262	G	A	nan
p.E484K	antibody epitope effects	Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Rappazzo et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Sun et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan
p.E484K	antibody epitope effects	Resistant to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold or greater reduction in neutralization (plus notable reduction in two unclassified mAbs).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma binding	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	Average extasciitilde5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andreano et al. (2020)	11262	G	A	nan
p.E484K	convalescent plasma escape	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Cele et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitilde1mo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	In 19 convalescent human sera extasciitilde1mo post infection had mild to moderate resistance against all samples.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	convalescent plasma escape	Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Liu et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1.1 antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	In 13 plasma collected extasciitilde1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Schmidt et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction ( extasciitilde1.7x across 10 convalescent sera from April 2020 infectees)	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	P.1.12, P.1.15, P.1.14, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11262	G	A	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutants of the 501Y.V2 "South African" lineage), while only 23% retained high titres	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wibmer et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 ("South African") lineage pseudovirus construct Only 3 of 44 convalescent sera (those with the highest titer, which correlated directly with initial infection severity) had high neutralization against this 501Y.V2 PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wibmer et al. (2021)	11262	G	A	nan
p.E484K	convalescent plasma escape	Subtype of the B.1.526 "New York" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in IC50 serum dilution concentration for 6 convalescent sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Zhou et al. (2021)	11262	G	A	nan
p.E484K	monoclonal antibody serial passage escape	The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barnes et al. (2020)	11262	G	A	nan
p.E484K	monoclonal antibody serial passage escape	Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Baum et al. (2020)	11262	G	A	nan
p.E484K	monoclonal antibody serial passage escape	Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Greaney et al. (2020)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	monoclonal antibody serial passage escape	Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Starr et al. (2021)	11262	G	A	nan
p.E484K	monoclonal antibody serial passage escape	Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan
p.E484K	monoclonal antibody serial passage escape	Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Weisblum et al. (2020)	11262	G	A	nan
p.E484K	outcome hazard ratio	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Funk et al. (2021)	11262	G	A	nan
p.E484K	outcome hazard ratio	In the Southern Brazilian stats of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves: The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ribas Freitas et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	outcome hazard ratio	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged 30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably, the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases. Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil. [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Santos de Oliveira et al. (2021)	11262	G	A	nan
p.E484K	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasci-tilde16x binding against this isolated mutation. Casirivimab lost extasci-tilde16x binding against this isolated mutation.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11262	G	A	nan
p.E484K	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11262	G	A	nan
p.E484K	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11262	G	A	nan
p.E484K	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasci-tilde64x binding against this double mutation. COR-101 lost extasci-tilde50x binding against this double mutation. Casirivimab lost extasci-tilde250x binding against this double mutation. Estesevimab lost extasci-tilde16x binding against this double mutation. Regdanvimab lost extasci-tilde32x binding against this double mutation. Tixagevimab lost extasci-tilde10x binding against this double mutation.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11262	G	A	nan
p.E484K	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11262	G	A	nan
p.E484K	pharmaceutical effectiveness	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Liu et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil re-infected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11262	G	A	nan
p.E484K	syncytium formation	extasciitilde50% Vero cell-membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, significantly higher than D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11262	G	A	nan
p.E484K	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11262	G	A	nan
p.E484K	trafficking	This variant alone shows a extasciitilde5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ferriera et al. (2021)	11262	G	A	nan
p.E484K	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11262	G	A	nan
p.E484K	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde11x, Vero extasciitilde10x, and Calu-3 extasciitilde11x. Compare to wild type at extasciitilde5x across cell types.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11262	G	A	nan
p.E484K	trafficking	extasciitilde6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11262	G	A	nan
p.E484K	trafficking	extasciitilde2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11262	G	A	nan
p.E484K	trafficking	extasciitilde12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (extasciitildeadditive effects of 501 and 484).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11262	G	A	nan
p.E484K	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing no change in infection rate amongst the cells.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ferreira et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	vaccine neutralization efficacy	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose) and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine showed a mean 2.8x decrease in neutralization efficacy.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ikegame et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference USA-WA1/2020 strain. 11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference USA-WA1/2020 strain.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Jangra et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	vaccine neutralization efficacy	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Janssen vaccine) against the variants containing the E484K substitution in the RBD were present but reduced (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Solfrosi et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.E484K	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan
p.E484K	vaccine neutralization efficacy	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Xie et al. (2021)	11262	G	A	nan
p.E484K	vaccinee plasma binding	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan
p.E484K	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11262	G	A	nan
p.E484K	virion structure	Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11262	G	A	nan
p.E484K	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11262	G	A	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	ACE2 receptor binding affinity	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with extasciitilde19x greater affinity than wild type.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	This variant appears twice in the experiments, with slightly different affinities (both extasciitilde1.2x decrease in binding relative to D614G) using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.	P.1.7	Gong et al. (2021)	2	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in "off-rate" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	P.1.7	Gong et al. (2021)	2	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	ACE2 receptor binding affinity	In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Li et al. (2020)	11263	A	G	nan
p.D614G	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11263	A	G	nan
p.D614G	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	A	G	nan
p.D614G	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.7	Gong et al. (2021)	2	A	G	nan
p.D614G	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.7	Gong et al. (2021)	2	A	G	nan
p.D614G	convalescent plasma binding	1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	convalescent plasma escape	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11263	A	G	nan
p.D614G	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	A	G	nan
p.D614G	immunosuppression variant emergence	Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Landis et al. (2021)	11263	A	G	nan
p.D614G	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11263	A	G	nan
p.D614G	syncytium formation	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	syncytium formation	extasciitilde50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, significantly higher than D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	syncytium formation	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	tissue specific neutralization	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal swab from different previously infected vaccinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against viral acquisition and infection of the oral-nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Planas et al. (2021)	11263	A	G	nan
p.D614G	trafficking	Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barrett et al. (2021)	11263	A	G	nan
p.D614G	trafficking	The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2. Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants, the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Daniloski et al. (2021)	11263	A	G	nan
p.D614G	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11263	A	G	nan
p.D614G	trafficking	No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	trafficking	extasciitilde4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde11x, Vero extasciitilde10x, and Calu-3 extasciitilde11x. Compare to wild type at extasciitilde5x across cell types.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	trafficking	extasciitilde6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde9x, Vero extasciitilde8x, and Calu-3 extasciitilde8x. Compare to wild type at extasciitilde5x across cell types.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	trafficking	extasciitilde4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11263	A	G	nan
p.D614G	trafficking	extasciitilde2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11263	A	G	nan
p.D614G	trafficking	extasciitilde12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction ( extasciitildeadditive effects of 501 and 484).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11263	A	G	nan
p.D614G	trafficking	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11267	A	G	nan
p.D614G	trafficking	Among S variants tested, the D614G mutant shows the highest cell entry ( extasciitilde3.5x wild type), as supported by structural and binding analyses.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ozono et al. (2020)	11263	A	G	nan
p.D614G	trafficking	We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type ( extasciitilde9-fold). This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion. D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may increase infectivity by assembling more functional S protein into the virion.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Zhang et al. (2020)	11263	A	G	nan
p.D614G	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9 days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose) and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700) 21 to 63 days post-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	A	G	nan
p.D614G	vaccine neutralization efficacy	No significant change in virus neutralization by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	P.1.7	Zuckerman et al. (2021)	2	A	G	nan
p.D614G	vaccinee plasma binding	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	vaccinee plasma binding	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.7	Gong et al. (2021)	2	A	G	nan
p.D614G	vaccinee plasma binding	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.7	Gong et al. (2021)	2	A	G	nan
p.D614G	vaccinee plasma binding	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D614G	vaccinee plasma binding	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	vaccinee plasma binding	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	A	G	nan
p.D614G	viral load	Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Plante et al. (2020)	11263	A	G	nan
p.D614G	virion structure	Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type)	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11263	A	G	nan
p.D614G	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	A	G	nan
p.D614G	virion structure	Negative stain EM shows increased proportion of “one-up” trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Weissman et al. (2020)	11263	A	G	nan
p.D614G	virion structure	CryoEM shows increased proportion of “one-up” trimer conformation of Spike proteins on the surface of virions, where the up conformation is presumed to be more likely to bind ACE2.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Yurkovetskiy et al. (2020)	11263	A	G	nan
p.D614G	virion structure	Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Zhang et al. (2020)	11263	A	G	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K378N	monoclonal antibody serial passage escape	Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody	P.1	Greaney et al. (2020)	128	G	T	nan
p.R246G	monoclonal antibody serial passage escape	Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28	P.1.12, P.1.12.1	McCallum et al. (2021)	4	A	G	nan
p.N501Y	ACE2 receptor binding affinity	The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity extasciitilde10 fold to KD extasciitilde7 nM, by increasing the k(on) extasciitilde1.8 fold and decreasing the k(off) by extasciitilde 7 fold as measured by surface plasmon resonance.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to extasciitilde15 fold higher than WT RBD (KD extasciitilde5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild type RBD by increasing the k(on) and decreasing the k(off) rate constants.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	This combination showed extasciitilde3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Collier et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with extasciitilde19x greater affinity that wild type.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gamez et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in "off-rate" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor, while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds 3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Laffebert et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Reported 10-fold increase in ACE2 binding vs wild-type (Kd	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Liu et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Studying the key covariants in lineage of concern 501Y.V2, observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Liu et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	extasciitilde4-fold increase in binding affinity vs wild type.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Motozono et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Using Microscale Thermophoresis, this variant binds ACE2 at nearly two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ramanathan et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Using Microscale Thermophoresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ramanathan et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	ACE2 receptor binding affinity	In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501 mutant residue with the ACE2 receptor, which in this strain is increased.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Santos and Passos (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Experimentally, ACE2 binding affinity increased 0.24 fold	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Starr et al. (2020)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus, but combined with the complete set of B.1.1.7 lineage variants no major change vs wild type affinity is observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tian et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tian et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Vogel et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Zahradnik et al. (2021)	11254	A	T	nan
p.N501Y	ACE2 receptor binding affinity	N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2. The additional interactions result in increased affinity of ACE2 for the N501Y mutant, accounting for its increased infectivity.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Zhu et al. (2021)	11254	A	T	nan
p.N501Y	T cell evasion	Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool, T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Reynolds et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Collier et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B.1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Haynes et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Klegerman et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Rees-Spear et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	Reduction in neutralization by mAbs COVA1-18 ( extasciitilde4x), COVA2-15 ( extasciitilde9x), S309 ( extasciitilde3x)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Shen et al. (2021)	11254	A	T	nan
p.N501Y	antibody epitope effects	4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Cele et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	In 19 convalescent human sera extasciitildelmo post infection had mild to moderate resistance against all samples.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitildelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe disease 21 to 63 days post-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11254	A	T	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	In 13 plasma collected extasciitilde1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	In 30 samples collected 111 to 260 days post onset of symptoms, the convalescent plasma can neutralize both the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Rathnasinghe et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	Neutralization activity of convalescent sera tested decreased extasciitilde2x with this B.1.1.7 pseudotyped virus.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Shen et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	Viruses containing the point mutations of B.1.1.7 showed that the single point mutations ( $\Delta$ 69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutants of the 501Y.V2 "South African" lineage), while only 23% retained high titres	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wibmer et al. (2021)	11254	A	T	nan
p.N501Y	convalescent plasma escape	Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 ("South African") lineage pseudovirus construct. Only 3 of 44 convalescent sera (those with the highest titer, which correlated directly with initial infection severity) had high neutralization against this 501Y.V2 PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wibmer et al. (2021)	11254	A	T	nan
p.N501Y	environmental condition stability	Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11254	A	T	nan
p.N501Y	homoplasy	Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia (same origin as UK), and South Africa (independent origin).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Flores-Alanis et al. (2021)	11254	A	T	nan
p.N501Y	immunosuppression variant emergence	Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2020)	11254	A	T	nan
p.N501Y	monoclonal antibody serial passage escape	In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan
p.N501Y	outcome hazard ratio	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Funk et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	outcome hazard ratio	In the Southern Brazilian states of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves: The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ribas Freitas et al. (2021)	11254	A	T	nan
p.N501Y	outcome hazard ratio	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged 30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably, the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases. Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil. [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Santos de Oliveira et al. (2021)	11254	A	T	nan
p.N501Y	pharmaceutical effectiveness	COR-101 lost extasci-tilde8x binding against this isolated mutation. Regdanvimab lost extasci-tilde6x binding against this isolated mutation.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11254	A	T	nan
p.N501Y	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11254	A	T	nan
p.N501Y	pharmaceutical effectiveness	Bamlanivimab (LY-CoV555) lost extasci-tilde64x binding against this double mutation. COR-101 lost extasci-tilde50x binding against this double mutation. Casirivimab lost extasci-tilde250x binding against this double mutation. Estesevimab lost extasci-tilde16x binding against this double mutation. Regdanvimab lost extasci-tilde32x binding against this double mutation. Tixagevimab lost extasci-tilde10x binding against this double mutation.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11254	A	T	nan
p.N501Y	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11254	A	T	nan
p.N501Y	pharmaceutical effectiveness	This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Liu et al. (2021)	11254	A	T	nan
p.N501Y	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11254	A	T	nan
p.N501Y	syncytium formation	Slight increase in Vero cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11254	A	T	nan
p.N501Y	syncytium formation	extasciitilde50% Vero cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, significantly higher than D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde9x, Vero extasciitilde8x, and Calu-3 extasciitilde8x. Compare to wild type at extasciitilde5x across cell types.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	extasciitilde4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	More efficient infectivity (24h) compared to wild type, in Caco-2 cells extasciitilde11x, Vero extasciitilde10x, and Calu-3 extasciitilde11x. Compare to wild type at extasciitilde5x across cell types.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	trafficking	extasciitilde6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kim et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11258	A	T	nan
p.N501Y	trafficking	extasciitilde12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction ( extasciitildeadditive effects of 501 and 484).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Motozono et al. (2021)	11254	A	T	nan
p.N501Y	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing slightly increased infection rate amongst the cells. [in what is essentially a replicate experiment in the same paper, because each B.1.351 lineage variant was independently evaluated and N501 is in both lineages, a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11254	A	T	nan
p.N501Y	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	vaccine neutralization efficacy	Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Bates et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone) relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Edara et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northern California during the study period, suggesting no effect of these variants on immune escape.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Jacobson et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Kuzmina et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Rathnasinghe et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, a modest decrease in neutralization by vaccine plasma was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.N501Y	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan
p.N501Y	vaccine neutralization efficacy	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Xie et al. (2021)	11254	A	T	nan
p.N501Y	vaccinee plasma binding	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan
p.N501Y	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11254	A	T	nan
p.N501Y	virion structure	Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11254	A	T	nan
p.N501Y	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11254	A	T	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T20N	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan
p.T20N	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan
p.T20N	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11259	C	A	nan
p.T20N	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	C	A	nan
p.T20N	antibody epitope effects	The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (extasciitildewild type), with only 64% neutralization at 10 g/mL. Residues 20, 18, and 138 form a cluster underlying the 245-259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed. Given that there is likely a single supersite ("i") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primarily anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with neutralization of Victoria (extasciitildewild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1, with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11259	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T20N	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitdelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	In 13 plasma collected extasciitdelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11259	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T20N	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11259	C	A	nan
p.T20N	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11259	C	A	nan
p.T20N	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	C	A	nan
p.T20N	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil re-infected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11259	C	A	nan
p.T20N	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11259	C	A	nan
p.T20N	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T20N	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T20N	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11259	C	A	nan
p.T20N	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11259	C	A	nan
p.T20N	vaccinee plasma binding	1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T20N	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	C	A	nan
p.T20N	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11259	C	A	nan
p.D138Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan
p.D138Y	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan
p.D138Y	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11263	G	T	nan
p.D138Y	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D138Y	antibody epitope effects	The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria ( extasciitildewild type), with only 64% neutralization at 10 g/mL. Residues 20, 18, and 138 form a cluster underlying the 245–259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed. Given that there is likely a single super-site ("i") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primarily anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with neutralization of Victoria ( extasciitildewild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1, with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11263	G	T	nan
p.D138Y	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma binding	1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D138Y	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	In 13 plasma collected extasciitidelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11263	G	T	nan
p.D138Y	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	G	T	nan
p.D138Y	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	G	T	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D138Y	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11263	G	T	nan
p.D138Y	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11263	G	T	nan
p.D138Y	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	G	T	nan
p.D138Y	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11263	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D138Y	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11263	G	T	nan
p.D138Y	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11263	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.D138Y	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	G	T	nan
p.D138Y	vaccinee plasma binding	1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan
p.D138Y	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	G	T	nan
p.D138Y	virion structure	Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11263	G	T	nan
p.D138Y	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	G	T	nan
p.L18F	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.L18F	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11263	C	T	nan
p.L18F	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.L18F	antibody epitope effects	The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (extasciitildewild type), with only 64% neutralization at 10 g/mL. Residues 20, 18, and 138 form a cluster underlying the 245-259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition, the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed. Given that there is likely a single supersite ("i") for potent NTD-binding antibodies, the binding of many of these are likely affected. Using 20 potent (primarily anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with neutralization of Victoria (extasciitildewild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1, with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11263	C	T	nan
p.L18F	antibody epitope effects	Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite "i", but no effect on other mAbs within that supersite	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11263	C	T	nan
p.L18F	antibody epitope effects	Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma binding	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Cele et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitildeImo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	convalescent plasma escape	In 13 plasma collected ex-tasciitilde1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.L18F	convalescent plasma escape	Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 ("South African") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated directly with initial infection severity) had high neutralization against this 501Y.V2 PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wibmer et al. (2021)	11263	C	T	nan
p.L18F	outcome hazard ratio	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Funk et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	outcome hazard ratio	In the Southern Brazilian states of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves: The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ribas Freitas et al. (2021)	11263	C	T	nan
p.L18F	outcome hazard ratio	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged 30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably, the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases. Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil. [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Santos de Oliveira et al. (2021)	11263	C	T	nan
p.L18F	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.L18F	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11263	C	T	nan
p.L18F	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.L18F	trafficking	Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection, showing mild decrease in infection rate amongst the cells, suggesting that this mutation does not contributing to cell entry fitness.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tada et al. (2021)	11263	C	T	nan
p.L18F	transmissibility	The relative transmissibility of P.1 estimated at the national level (Italy) varied according to the assumed degree of cross-protection granted by infection with other lineages and ranged from 1.12 (95%CI 1.03-1.23) in the case of complete immune evasion by P.1 to 1.39 (95%CI 1.26-1.56) in the case of complete cross-protection. PG: variant list has been abbreviated due to mixed K417 bases in this lineage, potential miscalls of deletions	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Stefanelli et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11263	C	T	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11263	C	T	nan
p.L18F	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.L18F	vaccinee plasma binding	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.L18F	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11263	C	T	nan
p.L18F	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11263	C	T	nan
p.T1027I	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan
p.T1027I	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan
p.T1027I	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11229	C	T	nan
p.T1027I	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma binding	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T1027I	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitilde1mo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	In 13 plasma collected extasciitilde1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11229	C	T	nan
p.T1027I	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11229	C	T	nan
p.T1027I	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11229	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T1027I	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil reinfected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11229	C	T	nan
p.T1027I	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11229	C	T	nan
p.T1027I	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11229	C	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.T1027I	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11229	C	T	nan
p.T1027I	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11229	C	T	nan
p.T1027I	vaccinee plasma binding	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan
p.T1027I	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11229	C	T	nan
p.T1027I	virion structure	Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11229	C	T	nan
p.V1176F	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11259	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.V1176F	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	In 13 plasma collected extasciitidelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11259	G	T	nan
p.V1176F	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11259	G	T	nan
p.V1176F	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	G	T	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.V1176F	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose) and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11259	G	T	nan
p.V1176F	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11259	G	T	nan
p.K417T	ACE2 receptor binding affinity	The K417T mutation decreased the affinity extasciilde2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11253	A	C	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K417T	ACE2 receptor binding affinity	The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild type RBD by increasing the k(on) and decreasing the k(off) rate constants.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Barton et al. (2021)	11253	A	C	nan
p.K417T	ACE2 receptor binding affinity	The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM), which binds with extascitilde19x greater affinity than wild type.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Dejnirattisai et al. (2021)	11253	A	C	nan
p.K417T	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan
p.K417T	ACE2 receptor binding affinity	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing P.1 aka Gamma) showed a 4.24x increase in binding (KD) relative to D614G.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan
p.K417T	anthropozoonotic events	Unlike wild type or B.1.1.7, P.1 lineage virus was able to infect and replicate in common lab mouse strains, with high titer.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Montagutelli et al. (2021)	11253	A	C	nan
p.K417T	antibody epitope effects	B.1.1.248 variant constellation ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07. B.1.1.248 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2676.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11253	A	C	nan
p.K417T	antibody epitope effects	Amongst RBD-targeting Emergency Use Authorized monoclonal antibody treatments CB6, LY-CoV555 and REGN10933 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1, but REGN10987 activity remains strong. RBD-targeting monoclonal antibodies 2-15 and C121 show abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1. N terminal domain targeting monoclonal antibodies 5-7, 4-8, 4-18 and 2-17 have abrogated neutralization activity against the ten key point mutations in Spike in the P.1 lineage vs wildtype or WA-1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma binding	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan



Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K417T	convalescent plasma escape	B.1.1.248 variant constellation in 10 convalescent human sera extasciitidelmo post infection had mild to moderate resistance against most samples, P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	B.1.1.7 variant constellation two-tailed Wilcoxon matched-pairs signed-rank test against 10 convalescent sera P	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	VSV pseudotype P.1 showed 4.8-fold decrease in NT50 vs wild type in sera from 9 ICU patients undergoing treatment in Germany (pre-variant infections).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 71.46 for P.1 virus. Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Luftig et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	In 13 plasma collected extasciitidelmo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization reduced to undetectable levels in many plasma for P.1 pseudotyped virus, as well as WT and other VOCs. [paper does not detail the P.1 variants used, using the most popular as a stand in]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	McCallum et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals based on 60 convalescent sera tested.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Mendes-Correa et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from convalescent plasma was seen against P.1 (3.5-fold). Neutralization against 10 convalescent plasma was slightly poorer (3.9-fold).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tang et al. (2021)	11253	A	C	nan
p.K417T	convalescent plasma escape	In convalescent sera one month or more post-infection in Spring 2020, an average 6.5x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.4x decrease against the full P.1 type vs WA-1 was observed, with better full P.1 ID50 reciprocal value compared to the 10-mutation model.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11253	A	C	nan
p.K417T	gene expression increase	Experimentally, Spike gene expression increased 0.25 fold	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Starr et al. (2020)	11253	A	C	nan
p.K417T	monoclonal antibody serial passage escape	Escape mutation against monoclonal antibody LY-CoV016	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Starr et al. (2021)	11253	A	C	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K417T	monoclonal antibody serial passage escape	In vitro selection against class 1 antibody C682	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11253	A	C	nan
p.K417T	outcome hazard ratio	On average across 7 European countries studied, using P.1 defining mutations: Significant shift to infection in those without pre-existing conditions (27.8% vs 89% for non-VOC cases). Significant increase in hospitalization rate (20% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.1% vs 0.6% for non-VOC cases). Significant increase in health care worker rate (19.8% vs 8.0% for non-VOC cases).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Funk et al. (2021)	11253	A	C	nan
p.K417T	outcome hazard ratio	In the Southern Brazilian state of Rio Grande do Sul, comparing pre-P.1 and post-P.1 waves: The increase in Case Fatality Rate occurred in a greatest intensity in the population between 20 and 59 years old and among patients without pre-existing risk conditions. Female 20 to 39 years old, with no pre-existing risk conditions, were at risk of death 5.65 times higher in February (95%CI	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Ribas Freitas et al. (2021)	11253	A	C	nan
p.K417T	outcome hazard ratio	In the Parana state of Brazil, patients aged 20-29 years experienced a tripling of their case fatality rate (CFR), from 0.04% to 0.13%, while those aged 30-39, 40-49, 50-59 experienced approximate CFR doubling comparing February to January in 2021. Notably, the observed CFR increase coincided with the second consecutive month of declining number of diagnosed SARS-CoV-2 cases. Taken together, these preliminary findings suggest significant increases in CFR in young and middle-aged adults after identification of a novel SARS-CoV-2 strain circulating in Brazil. [this is somewhat indirect evidence that assume greatly increasing proportion of P.1 cases in March (70%) compared to February, but the first official ID of P.1 in Parana state (Feb 16th) may be due to testing procedures rather than actual prevalence]	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Santos de Oliveira et al. (2021)	11253	A	C	nan
p.K417T	pharmaceutical effectiveness	COR-101 lost extasciitilde16x binding against this isolated mutation. Estesevimab lost extasciitilde16x binding against this isolated mutation. m396 lost extasciitilde8x binding against this isolated mutation.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11253	A	C	nan
p.K417T	pharmaceutical effectiveness	Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Engelhart et al. (2021)	11253	A	C	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K417T	pharmaceutical effectiveness	VSV pseudotype P.1 entry mediated by the S proteins of the P.1 variant was completely resistant to blocking by REGN10989 and Bamlanivimab. Cell fusion proficiency was slight impaired. Entry driven by the S proteins of the B.1.351 was partially resistant against Casirivimab.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11253	A	C	nan
p.K417T	reinfection	After a 128 day interval, a patient in Sao Paulo State, Brazil re-infected with P.1 (first episode likely predates P.1 emergence). Both cases were fairly mild (difficulty breathing, tiredness, dizziness and fatigue).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Malta Romano et al. (2021)	11253	A	C	nan
p.K417T	trafficking	extasciitilde6x cleavage of S2 relative to WA1 (D614G) wildtype by Gamma variant as measured by mass spectrometry of Vero-TMPRSS culture [no mutations directly at furin cleavage site, but H655Y is upstream] Compare to 4.5x or less for variants of concern with direct furin cleavage site mutations.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Esclera et al. (2021)	11253	A	C	nan
p.K417T	trafficking	VSV pseudotype P.1 showed slight decrease in cell entry relative to wild type in 262T and 263T-ACE2 (kidney) cell lines. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	Using P.1 defining mutations for Spike, observed 4x average decrease in neutralization efficiency (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Alenquer et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	In human sera 8 weeks post-vaccination with INO-4800, a extasciitilde2-fold reduction in P.1 neutralization was observed.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Andrade et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	The neutralizing activity of vaccine was slightly lower against B.1.1.248 variant constellation in sera tested from most of the 15 patients with the BNT162b2 mRNA vaccine. (Fig. 4)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Chen et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	Neutralization efficiency (ID50) against P.1 reduced 3.2x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Choi et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	ELISpot assays show T cell neutralization reduced by 16.6% in this B.1.1.248 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gallagher et al. (2021)	11253	A	C	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K417T	vaccine neutralization efficacy	Pseudotyped P.1 virus has reduced neutralization activity vs wild type: 6.7x (30 sera Pfizer median 9 days post 2nd dose) and 4.5x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Garcia-Beltran et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	1.15x *increase* in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	Among 46,884 HCWs in Manaus, Brazil vaccinated with at least one dose of CoronaVac, a 0.50-fold reduction (adjusted vaccine effectiveness, 49.6%: 95% CI, 11.3 - 71.4) in the odds of symptomatic SARS-CoV-2 infection was observed during the period 14 days or more after receiving the first dose. Estimated vaccine effectiveness of at least one dose against any SARS-CoV-2 infection was 35.1% (95% CI, -6.6 - 60.5) in the same time period.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hitchlings et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	VSV pseudotype P.1 showed 5.12-fold reduction in neutralization efficiency vs wild type in 15 Pfizer BNT162b2 vaccinee sera 13-15 days post second dose. Cell fusion proficiency was slight impaired.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Hoffman et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	Neutralizing antibody titers increased in previously infected vaccinees relative to uninfected vaccinees 4.3-fold against P.1 (contrast with 3.4 fold against original SARS-CoV-2).	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Leier et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	PBMCs of Pfizer/BioNTech BNT162b2 (n	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Tarke et al. (2021)	11253	A	C	nan
p.K417T	vaccine neutralization efficacy	In 12 Moderna vaccinee sera 15 days post second dose (43 days since first vaccination), an average 2.8x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 4.8x decrease against the full P.1 type vs WA-1 was observed, though overall with a higher ID50 reciprocal value. In 10 Pfizer vaccinee sera 7 days or more post second dose (28 days or more since first vaccination), an average 2.2x decrease in reciprocal ID50 value was observed ten key point mutations in Spike in the P.1 lineage vs wildtype. A 3.8x decrease against the full P.1 type vs WA-1 was observed, with similar variant ID50 reciprocal value.	P.1.12, P.1.15, P.1, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11253	A	C	nan

Mutations	Sub-category	Function	Lineages	Citation	Sequence Depth	Reference Allele	Alternate Allele	Alternate Frequency
p.K417T	vaccinee plasma binding	1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan
p.K417T	vaccinee plasma binding	This variant combination (representing P.1 aka Gamma) showed a 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. 1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Gong et al. (2021)	11253	A	C	nan
p.K417T	virion structure	Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type)	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Spratt et al. (2021)	11253	A	C	nan
p.K417T	virion structure	CryoEM reveals the P.1 trimer to adopt exclusively a conformation in which one of the receptor-binding domains is in the “up” position.	P.1.12, P.1.15, P.1.14, P.1.7, P.1.12.1, P.1.10, P.1.17	Wang et al. (2021)	11253	A	C	nan

The results here are in whole or part based upon data hosted at the Canadian VirusSeq Data Portal: <https://virusseq-dataportal.ca/>. We wish to acknowledge the following organisations/laboratories for contributing data to the Portal: Canadian Public Health Laboratory Network (CPHLN), CanCOGGeN VirusSeq and the list of labs available at <https://virusseq-dataportal.ca/acknowledgements>)